Maurizio Martelli
Maurizio Martelli is an expert in Hematology at Policlinico Umberto I (Italy). As of October 2026, ScienceLeadR ranks Maurizio Martelli in the top 1% of experts worldwide for Lymphoma, Lymphoproliferative Disorders and Leukemia. Maurizio Martelli has authored 410 publications, the most recent in 2026, and is an investigator in 43 clinical trials, 5 of them ongoing. SLR score: 2,000 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology - Infectiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1995 - 2026
Number : 410
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Different treatment eras for relapsed and refractory primary mediastinal B-cell lymphoma patients: accessibility to CAR T cells is associated with a better prognosis in a pooled analysis of the REPRIME-FIL and the CART-SIE studies. PMID 42779302 — cells, hematology, lymphoma, b-cell, lymphoma, therapeutics, b-lymphocytes, prognosis, salvage therapy, car-t cell | Haematologica | 2026 | 0 |
| Primary mediastinal B-cell lymphoma: a nationwide real-life retrospective study of first-line treatment approaches in Italy. PMID 42779329 — cells, hematology, lymphoma, b-cell, lymphoma, retrospective studies, therapeutics, b-lymphocytes | Haematologica | 2026 | 0 |
| Is There Still a Role for Autologous Stem Cell Transplantation in Older Adults with AML? PMID 42645796 — cells, mortality, microscopy, electron, scanning transmission, stem cells, leukemia, myeloid, acute, aged, transplants, cell transplantation, stem cell transplantation, transplantation | Hematol Rep | 2026 | 0 |
| Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants. PMID 42544796 — anticoagulants, thromboembolism, hemorrhage, incidence, hematologic neoplasms, neoplasms, risk factors, therapeutics, venous thromboembolism, heparin, low-molecular-weight, direct-acting oral anticoagulants | Eur J Haematol | 2026 | 0 |
| Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study. PMID 42285114 — headache, cells, muscles, sadness, lymphoma, b-cell, pain, arthralgia, lymphoma, lymphoma, large b-cell, diffuse, myalgia, signs and symptoms, appetite, drug-related side effects and adverse reactions, fatigue, nausea, physicians, prevalence, patient reported outcome measures, chills, therapeutics, deglutition, t-lymphocytes, b-lymphocytes, sleep initiation and maintenance disorders, dizziness, prospective studies, car-t cell | Lancet Haematol | 2026 | 0 |
Clinical Studies 43
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| MagnetisMM 6 A Phase 3 Study of Elranatamab (PF 06863135) Daratumumab Lenalidomide Versus Daratumumab Bortezomib Lenalidomide Dexamethasone in Transplant Ineligible Participants With Newly Diagnosed Multiple Myeloma 2024-514139-50-00 — safety, dexamethasone, bortezomib, multiple myeloma, lenalidomide, transplants | Phase 3 | Recruiting | 2022 |
| Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM 2022-501515-14-00 — cells, microscopy, electron, scanning transmission, multiple chronic conditions, stem cells, maintenance, multiple myeloma, lenalidomide, transplants, therapeutics, cell transplantation, stem cell transplantation, transplantation | Phase 3 | Recruiting | 2023 |
| Multi cohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia TAILOR 2023-504044-34-00 — leukemia, lymphocytic, chronic, b-cell, multiple chronic conditions, cohort studies, leukemia, leukemia, lymphoid, therapeutics | Phase 2 | Recruiting | 2024 |
| A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma NCT06588478 — cells, safety, lymphoma, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, protein-tyrosine kinases, agammaglobulinaemia tyrosine kinase, tyrosine, therapeutics, b-lymphocytes | Phase 2 | Recruiting | 2025 |
| A Physician Patient powered Cohort Registry (MY MYELOMA) NCT05001087 — registries, multiple myeloma, physicians | N/A | Recruiting | 2021 |
LeadR Networks
Main global connection map